Departamento de endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Seville, Spain.
Departamento de endocrinología y Nutrición, Hospital Universitario de Cruces, Bilbao, Spain.
J Comp Eff Res. 2021 Jul;10(10):815-821. doi: 10.2217/cer-2020-0264. Epub 2021 May 6.
Weight reduction and glycemic control are key goals during Type 2 diabetes management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in Type 2 diabetes patients in Spain. The study population comprised 1046 patients (594 with dapagliflozin, 452 with sitagliptin). Age was 61.8 ± 10.0 and 66.2 ± 11.4 years and glycosylated hemoglobin (HbA1c) 8.9 and 8.8%, respectively. The main end point (reduction in weight and HbA1c) was reached by 24.4 and 56.1% of patients, respectively; p < 0.05. This was confirmed with a propensity score matching analysis balanced for obesity-related variables at baseline. DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.
在 2 型糖尿病管理中，减轻体重和控制血糖是关键目标。然而，关于共转运蛋白 2 抑制剂的具体国家的真实世界数据很少。DAPA-RWE 是一项回顾性、多中心研究，比较了达格列净与西他列汀在西班牙 2 型糖尿病患者中的疗效。研究人群包括 1046 名患者（594 名接受达格列净治疗，452 名接受西他列汀治疗）。年龄分别为 61.8±10.0 和 66.2±11.4 岁，糖化血红蛋白（HbA1c）分别为 8.9%和 8.8%。主要终点（体重和 HbA1c 的降低）分别达到 24.4%和 56.1%的患者；p<0.05。这一结果通过基于基线肥胖相关变量的倾向评分匹配分析得到了证实。DAPA-RWE 证实，与西他列汀相比，达格列净在降低 HbA1c 和体重方面更有效。
